caffeine + paracetamol: clinical use

Prescribing considerations

• Confirm that no concurrent prescription or over-the-counter product contains paracetamol.
• Assess hepatic or renal impairment, alcohol use, low body weight, malnutrition and severe illness before recommending the product.
• Consider total caffeine exposure and susceptibility to insomnia, anxiety or palpitations.
• Persistent or frequent headache warrants clinical review, including consideration of analgesic-overuse headache.

Contraindications and cautions

• Hypersensitivity to paracetamol, caffeine or any excipient.
• Do not use with another paracetamol-containing product.
• The selected product should not be used during pregnancy or breastfeeding.
• Concomitant lithium use is not recommended.

Monitoring

• Routine monitoring is not generally required for occasional labelled use.
• In severe renal impairment, sepsis, malnutrition, chronic alcoholism or other glutathione-depleted states, remain alert for unexplained high-anion-gap metabolic acidosis, especially with flucloxacillin.
• Investigate suspected toxicity urgently after any overdose; early wellbeing does not exclude serious liver injury.

Clinical pharmacology

Paracetamol provides analgesic and antipyretic activity, while caffeine acts as a stimulant analgesic adjunct. Both are readily absorbed orally; the selected tablet’s disintegrant system accelerates dissolution without increasing the total extent of absorption compared with standard paracetamol–caffeine tablets.

Formulation and product differences

• The selected products are white to off-white, oval, film-coated tablets.
• The selected formulation contains a disintegrant system designed to accelerate tablet dissolution.
• Pack presentation and excipients can vary between licensed caffeine–paracetamol products; check the specific SmPC and leaflet.

Tablet

Route: Oral

Strengths: 500 mg + 65 mg